Mikael
Enveda Raises $150M Series D, Advances Nature-Inspired Drug Programs
Enveda Biosciences; Series D funding; $150 million; nature-inspired drug discovery; atopic dermatitis; immune diseases; Mikael Dolsten; biotech investment
Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development
Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D
Pfizer Faces Key R&D Challenges as Chief Scientific Officer Mikael Dolsten Departs
Pfizer, Mikael Dolsten, Chief Scientific Officer, R&D Challenges, Biopharma Industry
Pfizer’s R&D Chief Mikael Dolsten to Step Down After 15 Years of Leadership
Pfizer, Mikael Dolsten, Chief Scientific Officer, Research and Development, COVID-19 Vaccine, Successor Search